Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-10

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients

NCT02623309

Hematologic Neoplasms

COMPLETED PHASE3

Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

NCT04488432

Endocrine System Diseases Osteoporosis Metabolic Syndrome +1 more

COMPLETED

Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

NCT01050036

Leukemia, Myeloid

COMPLETED NA

Prospective and Retrospective Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia (Acute Leukemia HSCT Cohort)

NCT02344953

Acute Leukemia

UNKNOWN

Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03357172

Allogeneic Hematopoietic Stem Cell Transplantation

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Allo-HSCTs performed for the treatment of hematologic malignancies has been increasing in recent years. There is therefore a growing interest in the quality of life of these patients and in particular for the bone complications of the transplant. Indeed, it was found a high incidence of osteoporosis / osteopenia in this population associated with an increased risk of osteoporotic fracture from 6 to 9 times compared to the general population.

This study will evaluate the variation of mineral density and bone microarchitecture parameters by bone densitometry with measurement of trabecular bone score and fracturing risk before and after allogeneic HSCTs transplant, at predefined times. It's also evaluating pain scale, fracture incidence and bone remodeling markers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myeloid Leukemia, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with AML

Group Type OTHER

Bone osteodensitometry

Intervention Type OTHER

Evaluation of bone osteodensitometry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone osteodensitometry

Evaluation of bone osteodensitometry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant
* Patient affiliated to the social security system
* For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used.
* The patient must be able to comply with study visits and per protocol procedures
* Patient who has been informed of the study and has signed his informed consent

Exclusion Criteria

* Person under guardianship or curatorship, or unable to understand the purpose of the study.
* Hematologic malignancies other than AML
* History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and/or any solid cancer less than 5 years old
* History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies
* Known bone involvement related to AML at diagnosis
* Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies
* Corticotherapy \> 3 months at a dose \> 7.5mg/day prior to the diagnosis of hematological disease
* Autograft or anterior allograft
* Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR \< or = at 30ml / min / 1.73m2)
* Pregnant or lactating woman

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No